Denis Mee-Lee, MD
Psychiatry · Honolulu, HINPI 1730132416
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $407,634 of the $526,254 with a category attached, or 77.5%. It is spread thinly across 20 manufacturers, the largest accounting for just 20.6%. Among psychiatry clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,578 payments — averaging $333.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$108K
- Otsuka America Pharmaceutical, Inc.$107K
- Neurocrine Biosciences, Inc.$92K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$72K
- Alkermes, Inc.$66K
- AbbVie$65K
- plus $16K from 14 others
Across 14 payments — averaging $1446.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$11K
- Neurocrine Biosciences, Inc.$9K
What the payments were for
- Consulting fees$42,9958%
- Speaking & faculty fees$407,63477%
- Travel & lodging$41,9848%
- Food & beverage$33,4746%
- Education$1680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 231 | $108,295 |
| Otsuka America Pharmaceutical, Inc. | 193 | $107,069 |
| Neurocrine Biosciences, Inc. | 151 | $91,877 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 184 | $72,342 |
| Alkermes, Inc. | 172 | $65,820 |
| AbbVie(2 entities) | 173 | $64,805 |
| Sunovion Pharmaceuticals Inc. | 147 | $10,744 |
| Johnson & Johnson | 87 | $1,325 |
| Takeda Pharmaceuticals U.S.A., Inc. | 91 | $1,218 |
| Lundbeck LLC | 61 | $889 |
| Indivior Inc. | 31 | $552 |
| Vanda Pharmaceuticals Inc. | 19 | $408 |
| E.r. Squibb & Sons, L.L.C. | 14 | $319 |
| Axsome Therapeutics, Inc. | 4 | $187 |
| Merck | 9 | $175 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $72 |
| Eisai Inc. | 4 | $61 |
| Idorsia Pharmaceuticals US Inc | 2 | $45 |
| Janssen Scientific Affairs, LLC | 1 | $29 |
| Luye Pharma (USA) Ltd. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$252,660
- INGREZZA$89,765
- ABILIFY MAINTENA$71,173
- CAPLYTA$69,528
- ARISTADA INITIO$63,165
- VRAYLAR$62,301
- AUSTEDO$41,175
- REXULTI$37,649
- ABILIFY ASIMTUFII$36,712
- Austedo XR$33,914
- UZEDY$27,987
- LATUDA$8,476
- LYBALVI$1,375
- PERSERIS$125
- SPRAVATO$125
- Auvelity$109
How this compares
$526,254 in reported general payments places this provider in the 95th percentile of 183 psychiatry providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 110 | $399,632 |
| Austedo XrDeutetrabenazine | 48 | $362,935 |
| Abilify MaintenaAripiprazole | 86 | $239,891 |
| AristadaAripiprazole Lauroxil | 72 | $237,010 |
| IngrezzaValbenazine Tosylate | 16 | $143,702 |
| VraylarCariprazine Hcl | 52 | $77,285 |
| RexultiBrexpiprazole | 44 | $66,591 |
| TrintellixVortioxetine Hydrobromide | 78 | $42,815 |
| LybalviOlanzapine/Samidorphan Malate | 24 | $41,607 |
| UzedyRisperidone | 12 | $39,965 |
| Quetiapine Fumarate | 549 | $21,640 |
| FetzimaLevomilnacipran Hcl | 13 | $6,261 |
| Ziprasidone Hcl | 37 | $5,777 |
| Aripiprazole | 71 | $5,756 |
| Divalproex Sodium ErDivalproex Sodium | 51 | $4,387 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $108,295 | $402,90060 claims |
| Johnson & JohnsonInvega Sustenna | $1,325 | $399,632110 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $107,069 | $306,481130 claims |
| Alkermes, Inc.Aristada, Lybalvi | $65,820 | $278,61896 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $91,877 | $143,70216 claims |
| AbbVieVraylar, Fetzima | $64,805 | $83,54665 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $1,218 | $42,81578 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 psychiatry providers in Hawaii.
Other psychiatry in Honolulu
- David SteinHonolulu$186K
- Gregory YuenHonolulu$6K
- Raymond DavidsonHonolulu$6K
- Helen Blaisdell-BrennanHonolulu$6K
- Glorifin BelmonteHonolulu$5K
- Brett LuHonolulu$5K
- Donna McBrien SliwowskiHonolulu$4K
- Alan BuffensteinHonolulu$3K
- Nancy LuckieHonolulu$3K
- Angela KingHonolulu$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.